

RECENT PRICE	35.00	P/E RATIO	24.3 (Trailing: 24.6 Median: 15.0)	RELATIVE P/E RATIO	1.26	DIV'D YLD	3.2%	VALUE LINE
--------------	-------	-----------	---------------------------------------	--------------------	------	-----------	------	------------

1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	© VALUE LINE PUB. LLC	18-20
4.21	4.68	5.14	5.25	5.92	7.03	6.97	6.79	7.16	7.16	6.20	8.46	8.90	8.11	8.06	7.89	7.50	7.70	Sales per sh	8.45
1.02	1.18	1.50	1.72	2.21	2.84	2.80	2.85	3.03	1.94	1.66	2.09	2.34	2.35	2.77	2.33	2.40	2.70	"Cash Flow" per sh	3.35
.87	1.02	1.31	1.53	1.75	2.12	2.02	2.06	2.20	1.18	1.23	1.03	1.11	1.26	1.65	1.41	1.45	1.70	Earnings per sh <sup>A G</sup>	2.30
.31	.36	.44	.52	.60	.68	.76	.96	1.16	1.28	.80	.72	.80	.88	.96	1.04	1.12	1.18	Div'ds Decl'd per sh <sup>B</sup>	1.36
.41	.35	.35	.29	.35	.35	.29	.29	.28	.25	.15	.19	.22	.18	.19	.19	.20	.20	Cap'l Spending per sh	.20
2.31	2.55	2.91	3.24	8.53	9.10	8.88	9.98	9.60	8.52	11.15	10.95	10.84	11.16	11.92	11.33	11.30	11.80	Book Value per sh <sup>C</sup>	13.80
3847.0	6314.0	6277.0	6162.0	7629.0	7473.0	7361.0	7124.0	6761.0	6746.0	8070.0	8012.0	7575.0	7276.0	6399.0	6291.0	6200.0	6100.0	Common Shs Outst'g <sup>D</sup>	5800.00
44.3	40.7	31.8	22.8	18.2	15.6	12.7	12.5	11.5	16.4	12.8	16.3	17.6	18.4	17.6	21.5	<b>Bold figures are Value Line estimates</b>		Avg Ann'l P/E Ratio	17.0
2.53	2.65	1.63	1.25	1.04	.82	.68	.67	.61	.99	.85	1.04	1.10	1.17	.99	1.12			Relative P/E Ratio	1.05
.8%	.9%	1.1%	1.5%	1.9%	2.1%	3.0%	3.7%	4.6%	6.6%	5.1%	4.3%	4.1%	3.8%	3.3%	3.4%			Avg Ann'l Div'd Yield	3.5%

<b>(\$MILL.)</b>					
Cash Assets	32708	32408	36122	<b>BUSINESS:</b> Pfizer Inc. is a research-based, global biopharmaceutical company engaging in the discovery, development, manufacture, and sale of healthcare products. Portfolio includes medicines, vaccines, and various consumer healthcare products. Manages operations through a structure consisting of three businesses: Global Innovative Pharmaceutical (GIP), Global Vaccines, Oncology, and	Consumer Healthcare (VOC), and Global Established Pharmaceutical (GEP). Top-selling products '14: <i>Lyrica</i> , <i>Prenvan</i> , <i>Enbrel</i> , and <i>Celebrex</i> . Has 78,300 employees. Dir's/Off. own less than 1% of common; BlackRock, 7.1%; Vanguard, 5.5% (3/15 proxy). Chrmn/CEO: Ian C. Read, Inc.: Del. Addr.: 235 East 42nd St., New York, NY 10017. Tel.: 212-733-2323. Internet: <a href="http://www.pfizer.com">www.pfizer.com</a>
Receivables	12378	9357	8669		
Inventory (LIFO)	7063	6166	5663		
Other	9266	8313	7248		
Current Assets	61415	56244	57702		
Accts Payable	4264	3234	3440	<b>Pfizer inked a deal with Hospira in</b>	a share, on revenues of \$44.5 billion to
Debt Due	6424	6027	5141		
Other	17931	14105	13050		
Current Liab.	28619	23366	21631		

Calendar	QUARTERLY SALES (\$ mill.)				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2012	14885	15057	13976	15068	58986
2013	12410	12973	12643	13558	51584
2014	11353	12773	12361	13118	49605
2015	10800	11700	11500	12500	46500
2016	10500	11500	12000	13000	47000

Calendar	QUARTERLY DIVIDENDS PAID <sup>B</sup>				Full Year
	Mar.31	Jun.30	Sep.30	Dec.31	
2011	.20	.20	.20	.20	.80
2012	.22	.22	.22	.22	.88
2013	.24	.24	.24	.24	.96
2014	.26	.26	.26	.26	1.04
2015	.28				

© 2015 Value Line Publishing LLC. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product.